Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NCF1 | P14598 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 3/20 | 0.49 |
| ▸ | CDK4 | P11802 | 2/20 | 0.49 |
| ▸ | CCND1 | P24385 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19009075 | 0.85 | NR4A2 (0.59) | MEN1HTTKMT2ACYP2C19MAPT | |
| SCHEMBL28511396 | 0.85 | KMT2A (0.67) | MEN1HTTKMT2AMAPTTDP1 | |
| SCHEMBL30148662 | 0.80 | SOS1 (0.46) | CYP2C19L3MBTL1CCNE2CCNE1CDK2 | |
| SCHEMBL30014678 | 0.79 | SOS1 (0.70) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL1238925 | 0.76 | CYP1A2 (0.60) | MEN1HTTKMT2ACYP2C19MAPT | |
| SCHEMBL30307409 | 0.76 | GALR3 (0.59) | MEN1HTTKMT2AMAPTGALR3 | |
| SCHEMBL30594935 | 0.76 | SOS1 (0.49) | L3MBTL1 | |
| SCHEMBL14451007 | 0.75 | NUDT1 (0.56) | MEN1HTTKMT2AMAPTL3MBTL1 | |
| SCHEMBL12763789 | 0.75 | TLR7 (0.66) | MEN1HTTKMT2ACYP2C19L3MBTL1 | |
| SCHEMBL4903031 | 0.75 | NQO2 (0.59) | MEN1HTTKMT2ACYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420670-B2 | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | claimed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | claimed |
| EP-2178842-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2010-04-28 | — | — | EP | claimed |
| WO-2009024611-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | claimed |
| US-8420670-B2 | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | disclosed |
| EP-2178842-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009024611-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GDI2, GDI1, NQO2 | MEN1 1704/4885HTT 2044/4885KMT2A 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.